News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pulmatrix Announces Grant of Patent Supporting Its Novel Pulmonary Drug Therapies



1/5/2012 5:59:04 AM

LEXINGTON, Mass.--(BUSINESS WIRE)--Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, announced that the European Patent Office has granted Pulmatrix’s patent number EP 2315580 B1 entitled “Pharmaceutical formulations and methods for treating respiratory tract infections”, a patent relating to compositions and uses of the company’s inhaled drug therapies. The newly-granted patent describes both dry powder and liquid formulations with optimized ranges of the formulation components, and also describes methods for treating respiratory infections and diseases as well as methods for treating acute exacerbations of asthma, chronic obstructive pulmonary disease (COPD) or cystic fibrosis (CF). The granted patent also specifically contains composition of matter claims covering Pulmatrix’s lead dry powder iCALM formulation, PUR118, which is being evaluated in ongoing clinical trials, including two on-going Phase 1b studies in patients with COPD which includes patients with emphysema and chronic bronchitis.

Read at BioSpace.com


comments powered by Disqus
Pulmatrix
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES